This Article Full Text Full Text (PDF) All Versions of this Article: 1055-9965.EPI-06-0416v1 15/11/2027    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vogel, V. G. Search for Related Content PubMed PubMed Citation Articles by Vogel, V. G.

Identifying and Screening Patients at Risk of Second Cancers

Department of Medicine, Section of Hematology and Oncology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Requests for reprints: Victor G. Vogel, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213-3180. Phone: 412-641-6500; Fax: 412-641-6461. E-mail: vvogel{at}magee.edu

Background: The average age of the U.S. population is increasing, and cancer incidence increases with age. Both improved early detection of first malignancies and effective primary oncologic therapy have led to prolonged survival, and the risk of secondary malignancies has consequently increased. A few anatomic sites are at increased risk for second malignancies within the same organ: breast, colon and rectum, lung, head and neck (or upper aerodigestive malignancies), prostate, and the uterine cervix. Some of the cancers also incur a risk for a second malignancy at another anatomic site. In addition, there are well-described clinical genetic syndromes that, as unique clinical entities, predispose to second malignant tumors.

Methods/Results: In this review, we focus on issues related to the risk of second malignancies among patients with primary breast, colon, lung and head and neck, prostate, and cervical cancers that comprise the most common sites of primary malignancy among patients in the United States. We review recent data related to both established and new screening strategies at these sites.

Conclusions: There is some evidence that screening will improve outcomes among patients who may develop second malignancies, although the data are limited. The optimal screening modalities and strategies to reduce mortality from second malignancies remain to be defined for most tumor sites. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2027–32)

This article has been cited by other articles:

				H.-S. Hofmann, H. Neef, and P. Schmidt Primary lung cancer and extrapulmonary malignancy. Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 653 - 658. [Abstract] [Full Text] [PDF]